Loading news...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in Globus Medical, Inc. (NYSE: GMED) by 28.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,202 shares of the medical device company's stock after selling 57,434 shares during the
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Anchor Capital Advisors LLC raised its position in shares of Globus Medical, Inc. (NYSE: GMED) by 42.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 800,282 shares of the medical device company's stock after purchasing
Globus Medical is growing musculoskeletal market share with new product launches, strong finances and international expansion plans.
The global AI market is projected to reach over $3 trillion by 2033, driven by growing investments from big tech, broader adoption, and booming data center requirements. Companies that provide AI software, hardware, and services are poised to exploit the megatrend and deliver significant profitable growth. AI stocks have outperformed over the past year, led by chipmakers, hyperscaler suppliers, and EV manufacturers.
Medical sector leader Globus Medical is in a buy zone from a cup-with-handle base that has a buy point of 92.48.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Globus Medical (GMED) moved sharply higher after management laid out an outlook that came in ahead of expectations, prompting investors to reassess the company'
Trump puts pressure on defense contractors, Globus Medical soars on preliminary results, and more
Globus Medical has provided preliminary fourth-quarter 2025 financial results. The company forecasts a more robust bottom line in 2026 than what analysts anticipate.
AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-reported basis. Full year 2025 sales are expected to be approximately $2.936 billion, an increase of 16.5 percent over the prior year on an as-reported basis.
Shares of Globus Medical, Inc. (NYSE: GMED - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here are some surging MedTech stocks - GMED, TMDX and HIMS - that may face slowing momentum in 2026.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Fisher Asset Management LLC lessened its stake in Globus Medical, Inc. (NYSE: GMED) by 12.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 288,073 shares of the medical device company's stock after selling 42,835 shares during the quarter. Fisher Asset Management LLC
Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?